RxDoctor Payments Data

Rae Ringenberg, MD

Family Medicine · Apopka, FLNPI 1477500494

Payments from drug & device makers

$6,002in general payments, 2019–2025

Across 62 payments — averaging $96.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$678
  • GSK$635
  • Amgen$572
  • Lilly USA, LLC$440
  • Boehringer Ingelheim$356
  • plus $2K from 9 others

What the payments were for

  • Speaking & faculty fees$601%
  • Food & beverage$5,91999%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca16$1,741
Novo Nordisk6$678
GSK9$635
Amgen(2 entities)5$572
Lilly USA, LLC4$440
Boehringer Ingelheim3$356
AbbVie3$351
Amarin Pharma, Inc.3$256
Johnson & Johnson3$223
Abbott5$211
Genentech USA, Inc.1$125
Bayer1$125
Merck1$117
Novartis1$111
Sanofi1$60

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,002 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$46,171
Medicare patients
133
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol22$24,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$23,028
EliquisApixaban18$20,078
OzempicSemaglutide16$15,674
Janumet XrSitagliptin Phos/Metformin Hcl14$12,360
Atorvastatin Calcium304$3,756
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$2,576
Gabapentin69$2,057
Omeprazole77$1,660
Celecoxib26$1,518
Amlodipine Besylate270$1,417
Levothyroxine Sodium124$1,353
Rosuvastatin Calcium89$1,336
Montelukast Sodium82$1,132
Lisinopril176$1,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,741$24,89122 claims
GSKTrelegy Ellipta$635$23,02819 claims
Novo NordiskOzempic$678$15,67416 claims
MerckJanumet Xr$117$12,36014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Apopka

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →